LATE-BREAKING ABSTRACT: Study to understand mortality and morbidIty in COPD (SUMMIT)

Chronic obstructive pulmonary disease (COPD) is recognized as having significant systemic manifestations associated with increased mortality and morbidity (Agusti, Proc Am Thorac Soc 2005;2:367-70), in particular cardiovascular (CV) disease. More patients with moderate COPD die from lung cancer and CV diseases than from COPD (Calverley, N Engl J Med 2007;356:775-89).Post-hoc analyses from the TORCH study suggest an inhaled corticosteroid/long acting beta2 agonist (ICS/LABA) combination may reduce mortality and CV events (e.g. acute coronary syndrome [ACS] and stroke) in patients with moderate COPD (≥50% predicted FEV1) and several risk factors for CV disease.The Study to Understand Mortality and MorbidITy in COPD (SUMMIT) study (Vestbo, Eur Respir J 2013;41:1017-22) was designed to assess impact of Fluticasone Furoate (FF)/Vilanterol (VI) (FF/VI) compared with placebo on survival in patients with moderate COPD (>50 and <70 % predicted FEV1) and a history of or multiple risk factors for CV disease.The primary endpoint is all-cause mortality and secondary endpoints are rate of decline in FEV1 and time to composite CV event (on-treatment CV death, ACS [i.e. MI and unstable angina], stroke and TIA).Over 16,000 patients were randomized in 43 countries between March 2011 and March 2014 and were assigned to either FF/VI 100/25mcg, FF 100mcg, VI 25mcg or placebo, in addition to usual CV medication. This was an event driven study that reached the Common End Date January 25, 2...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: 1.1 Clinical Problems Source Type: research